Dechra Pharmaceuticals

Equities

DPH

GB0009633180

Delayed London S.E. Other stock markets 01:00:00 16/01/2024 pm IST			5-day change	1st Jan Change
3,866 ^GBX	-.--%		-.--%	+0.21%

10/06	Dechra Pharmaceuticals Limited Appoints Jonathan David Lang as Director	CI
15/04	Dechra Pharmaceuticals Limited acquired 33.34% stake in STEM Animal Health Inc.	CI

Dechra Pharmaceuticals plc acquired RxVet Limited.

January 09, 2018

Dechra Pharmaceuticals plc (LSE:DPH) acquired RxVet Limited in December 2018. RxVet Limited reported revenue of NZD 1.4 million in the year to March 2017. DLA Piper acted as legal advisor to Dechra Phatrmaceuticals Plc. Dechra Pharmaceuticals plc (LSE:DPH) completed the acquisition of RxVet Limited in December 2018.

Latest news about Dechra Pharmaceuticals

Dechra Pharmaceuticals Limited Appoints Jonathan David Lang as Director	10/06	CI
Dechra Pharmaceuticals Limited acquired 33.34% stake in STEM Animal Health Inc.	15/04	CI
Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.	11/04	CI
Dechra Group Holdings Limited Appoints Paul Nicholas Sandland as Director	09/04	CI
Dechra Group Holdings Limited Appoints Ian David Page as Director	09/04	CI
Dechra Group Holdings Limited Announces Resignation of Thomas Spicer as Director	09/04	CI
Dechra Group Holdings Limited Announces Resignation of Anthony Santospirito as Director	09/04	CI
Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director	09/04	CI
Stocks slump as Fed rate cut hope dwindles	17/01	AN
Dechra Pharmaceuticals Delists From London Bourse Following Freya Bidco’s Takeover	17/01	MT
EQT's Freya Bidco Completes Dechra Pharmaceuticals Purchase	16/01	MT
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index	16/01	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-World Index	16/01	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 350 Index	16/01	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index	16/01	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 350 (Ex Investment Companies) Index	16/01	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from S&P Global BMI Index	16/01	CI
EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC.	16/01	CI
Persimmon to replace outbound FTSE 100 constituent Dechra	12/01	AN
EMEA Morning Briefing : Markets to Track Fresh Middle East Tensions	12/01	DJ
EU clears Dechra Pharmaceuticals takeover by EQT funds	27/12	AN
EQT's Dechra Takeover to Become Effective in Mid-January 2024	27/12	MT
EQT's Takeover of Dechra Pharmaceuticals Gets EU Antitrust Regulator's Nod	22/12	MT
Inchcape to appoint Jerry Buhlmann to chair board of directors from May	14/12	AN
EQT Secures Australian Nod for Dechra Pharmaceuticals Takeover	30/11	MT

Chart Dechra Pharmaceuticals

Duration

Period

More charts

Company Profile

Dechra Pharmaceuticals PLC specializes in the manufacturing and marketing of veterinary pharmaceutical products. Net sales break down by family of products as follows: - companion animal products (74.6%); - food producing animal products (11.5%); - equine health products (7.3%); - animal feeds (5.1%); - other (1.5%): products manufactured by third parties. Net sales are distributed geographically as follows: the United Kingdom (8.5%), Germany (9.2%), Europe (31.2%), the United States (37.9%) and other (13.2%).

Sector

More about the company

Income Statement Evolution

More financial data